India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
AI-powered sentiment analysis is giving real estate investors a major edge by scanning millions of online conversations to detect market shifts long before traditional data responds. From predicting neighborhood momentum to spotting declining tenant satisfaction, this technology captures real-time public emotion across office, retail, and multifamily sectors. As trends in sentiment become as important as demographics and NOI, professionals who understand these tools will stay ahead of the next market move.
Florida lawmakers are racing toward a high-stakes finish to the legislative session as a sweeping property tax overhaul triggers fierce debate. The House is pushing to eliminate most non-school property taxes on primary homes, while the Senate urges caution and Gov. Ron DeSantis floats even bigger changes. With Democrats warning of budget crises and only weeks left to strike a deal, the future of Florida’s tax structure—and its real estate market—hangs in the balance.
Florida homeowners are getting rare financial relief as the emergency insurance assessment—added after multiple insurers collapsed post‑Hurricane Ian—has been paid off two years early. The early payoff wipes out the charge of about $30 per household per year and delivers more than $650 million in statewide savings. With the insurance market stabilizing faster than expected, real estate and insurance professionals can expect a slightly more favorable environment for buyers and policyholders alike.
After years of pandemic‑driven disruption, rising vacancies, and interest‑rate volatility, confidence is finally returning to commercial real estate. Major analysts report that leasing activity is accelerating, investor appetite is rising, and high‑quality properties are leading the rebound. With investment volumes expected to jump and vacancies beginning to fall, 2026 is shaping up to be the long‑awaited turning point for the industry.
Sioux Falls enters 2026 with a commercial real estate market outperforming nearly every regional competitor. Fueled by strong fundamentals, major private investment, and confidence across all sectors, the city is positioned for what experts call “white‑hot economic activity.” From booming land sales and rising retail absorption to stabilizing office and industrial sectors, the metro’s momentum is undeniable—making it a prime environment for real estate professionals and investors looking for opportunity.
Florida lawmakers have advanced HB 767, a major insurance transparency bill that would create a statewide online rate database, boost consumer education, and prevent insurers from using land value to inflate premiums. The proposal promises clearer insurance data and stronger accountability—bringing much‑needed relief and insight to homeowners, real estate agents, mortgage professionals, and insurance producers across the state.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
